Synopsys Inc. (SNPS)

Synopsys Inc. enters mid-November with its share price sitting almost exactly on its 20-day EMA at $460.20, after a month in which it fell 9.81%. The stock is still above its 50-day and 200-day moving averages ($442.50 and $441.66), and analysts remain strongly positive: 23 of 25 rate it Buy, and the median 12-month target of $600.00 sits 30.4% above the price. The tension is valuation. At a trailing P/E of 81.02, the stock trades at a premium to the sector median of 35.1, so the case for owning it rests on continued revenue growth that is running well ahead of peers.

The stock's most recent earnings report, dated August 26, 2026, carried adjusted EPS of $3.91, a beat of 6.54% above the estimate, and the share price rose 13.39% in the first trading session after it. That reaction is the largest single-day move on the earnings record. Over the last eight reports, seven beat the EPS estimate, but five of those seven beats were followed by a lower share price in the first session. The market has therefore not treated a beat as a guarantee of a rise; the reaction depends on what investors expect next. The May 27, 2026 report beat by 6.01% and was followed by an 8.61% drop, and the February 25, 2026 beat of 5.90% was followed by a 5.16% fall.

Profitability has not kept pace. The net profit margin is 11.43% and the operating margin 14.52%, but return on equity is 3.66%, below the sector median of 13.4%. The debt-to-equity ratio of 0.35 is modest, so the balance sheet is not the constraint; the gap is in how much profit the equity base generates.

At a trailing P/E of 81.02 the stock is priced at a premium of 130.8% to the sector median of 35.1, and the price-to-sales ratio of 9.33 sits 22.8% above the sector median of 7.6. Trailing GAAP earnings of $5.66 per share are the base for that P/E. Investors paying this multiple are betting that revenue growth keeps converting into earnings at a faster pace than it has so far. Because the return on equity is still below peers, that conversion is the point the bull case must prove.

Insiders sold $84.5M of stock over the last 18 months across 16 sales, against one open-market purchase worth $149K. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less information than purchases would. Meanwhile, the analyst base has moved toward the stock: 19 of 25 ratings were Buy three months ago and 23 of 25 are Buy or Strong Buy now. HSBC upgraded the stock to Buy from Hold on September 25, 2026, and Morgan Stanley kept its Overweight rating on October 20, 2026.